- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05079451
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35222
- Alabama CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Step 0 Inclusion Criteria:
- Ability and willingness of participant to provide informed consent to enter the Screening and Pre-Entry segment of the study.
- Individuals age ≥18 to ≤70 years.
- Weight greater than or equal to 50 kg (110 pounds) and less than or equal to 115 kg (253.5 pounds).
- Documented HIV-1 infection.
- For participants who can become pregnant, a negative pregnancy test at Screening must be obtained.
- For participants who can become pregnant, participant must agree to use two methods of contraception.
- Participants who can impregnate a partner and who are engaging in sexual activity that could lead to pregnancy must agree to use condoms from 10 days prior to the first dose of study drugs, while receiving the study drugs, and for 12 months after the last dose of study drug to avoid impregnating a partner who can get pregnant.
- Willingness to use barrier protection (male or female) during sexual activity.
Step 0 Exclusion Criteria:
1. Currently breastfeeding or pregnancy.
Step 1 Inclusion Criteria:
- On stable suppressive Antiretroviral Therapy (ART) for at least 48 weeks prior to Step 1 study entry with no interruption of ART for 7 consecutive days or longer in the 48 weeks prior to entry in Step 1.
- If on an NNRTI-based regimen, willing to switch to an integrase inhibitor-based regimen at least 4 weeks prior to discontinuing ART.
- CD4+ cell count >450 cells/µL obtained within 90 days prior to study Step 1 entry at any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent.
- CD4+ cell % ≥15% obtained within 90 days prior to study Step 1 entry at any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent.
- Nadir CD4+ cell count ≥200 cells/µL. (NOTE: If documentation is not available, then participant recall is acceptable.)
- Plasma HIV-1 RNA levels of <50 copies/mL for at least 48 weeks prior to Step 1 entry at any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent (NOTE: At least two viral load measurements within 48 weeks prior to the Step 0 screening visit must be available for review. A single plasma HIV-1 RNA >50 copies/mL but <200 copies/mL that is followed by an HIV-1 RNA <50 copies/mL is permitted.)
- 3BNC117-LS IC90 less than 1 mcg/mL and MPI >98% in PBMCs or plasma with the Monogram PhenoSense assay. (NOTE: Monogram PhenoSense assay obtained for eligibility to other clinical trials may be used for eligibility.)
- 10-1074-LS IC90 less than 1 mcg/mL and MPI >98% in PBMCs or plasma with the Monogram PhenoSense assay. (NOTE: Monogram PhenoSense assay obtained for eligibility to other clinical trials may be used for eligibility.)
The following laboratory values obtained within 90 days prior to Step 1 entry by any US laboratory that has a CLIA certification or its equivalent:
- absolute neutrophil count (ANC) ˃1,000/mm3
- hemoglobin >10 g/dL
- platelet count ˃100,000/mm3
- eGFR ≥60 mL/min/1.73m2
- AST (SGOT), ALT (SGPT), and total bilirubin <1.5 x ULN
- alkaline phosphatase less than 1.5 x ULN
- Completion of pre-entry leukapheresis with documentation of at least 1 billion cells of stored PBMC (e.g., ≥20 aliquots of 50,000,000 PBMC). Sites must receive confirmation from the processing lab via phone, email, or fax that specimens have been entered into the ACTG's Laboratory Data Management System (LDMS).
- For participants who can become pregnant, a negative pregnancy test at Screening must be obtained.
Step 1 Exclusion Criteria:
- History of AIDS-defining illness within 36 months prior to study Step 1 entry
- Any clinically significant acute or chronic medical condition (such as autoimmune diseases or active tuberculosis), other than HIV infection, that in the opinion of the investigator would preclude participation.
- Any history of an HIV-associated malignancy, including Kaposi's sarcoma, or any type of lymphoma or virus-associated cancers.
- History of Progressive Multifocal Leukoencephalopathy (PML).
- Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery within 36 months prior to Step 1 study entry or for whom such therapies are expected in the subsequent 12 months. (NOTE: Minor surgical removal of localized skin cancers (squamous cell carcinoma, basal cell carcinoma) is not exclusionary.)
- Receipt of cabotegravir-LA IM or rilpivirine-LA IM within 24 months prior to Step 1 study entry.
- Known resistance to all drugs within two or more ARV drug classes. (NOTE: M184V/I is an exception, and should not be considered when assessing this criterion. Prior HIV resistance testing is not required.)
- History of systemic corticosteroids (long-term use), immunosuppressive anti-cancer or other immunosuppressive agents, interleukins, systemic interferons, systemic chemotherapy, or other medications considered significant by the investigator within the 24 weeks prior to Step 1 study entry.
- ART initiated during acute infection (defined as p24, HIV NAAT, or HIV RNA PCR positive, and negative or indeterminate HIV antibody testing).
- Any history of receipt of therapeutic HIV vaccine or HIV monoclonal antibody therapy.
- Participation in any clinical study of an investigational product within 12 weeks prior to Step 1 study entry or expected participation in such a study during this study.
- Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.
- Known allergy/sensitivity or any hypersensitivity to components of either study agent or their formulation.
History of or current clinical atherosclerotic cardiovascular disease (ASCVD), as defined by 2013 ACC/AHA guidelines, including a previous diagnosis of any of the following:
- Acute myocardial infarction
- Acute coronary syndromes
- Stable or unstable angina
- Coronary or other arterial revascularization
- Stroke
- Transient ischemic attack
- Peripheral arterial disease presumed to be of atherosclerotic origin
- 10-year ASCVD risk score estimated by Pooled Cohort Equations >20% in participants ≥40 and ≤ 70 years of age.
- Diagnosis of cirrhosis
- Diagnosis of untreated syphilis, gonorrhea, or chlamydia. (NOTE: Candidates who began treatment for any of the above are not excluded.)
Step 2 Inclusion Criteria:
- Willingness to continue the analytical treatment interruption (ATI) and be monitored.
Step 2 Exclusion Criteria:
- None.
Step 3 Inclusion Criteria:
Meet ONE of the following:
- Meeting one or more ART restart criteria as defined in the study protocol
- Despite completing 72 weeks of ATI without meeting one or more ART restart criteria, declines participation in A5385, or is unable to enter A5385.
Step 3 Exclusion Criteria:
- None.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study Participants
Participants will receive an infusion of both study drugs (3BNC117-LS and 10-1074-LS) and will then discontinue antiretroviral therapy two days later.
|
3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes.
The total time needed to administer the study drug may be longer, based on factors such as participant tolerance.
The participant's dose will be calculated using their most current weight on record.
10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes.
The total time needed to administer the study drug may be longer, based on factors such as participant tolerance.
The participant's dose will be calculated using their most current weight on record.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of Grade ≥3 systemic AE related to combination of 3BNC117-LS and 10-1074-LS or premature study treatment discontinuation due to an AE (regardless of grade) that is related to combination of 3BNC117-LS and 10-1074-LS.
Time Frame: 72 weeks
|
72 weeks
|
Viral rebound defined as confirmed HIV-1 RNA >200 copies/mL at or prior to week 24 of ART discontinuation.
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Actual body exposure to drug after administration of a dose of the drug (known as the "Area under the curve (AUC)") of weeks 0-24 for 3BNC117-LS and 10-1074-LS.
Time Frame: 72 weeks
|
72 weeks
|
Actual body exposure to drug after administration of a dose of the drug (known as the "Area under the curve (AUC)") of weeks 0-infinity for 3BNC117-LS and 10-1074-LS.
Time Frame: 72 weeks
|
72 weeks
|
Frequency of induced anti-study drug antibodies (ADA).
Time Frame: 72 weeks
|
72 weeks
|
CD4+ cell counts (cells/mm3) through entire study follow-up.
Time Frame: 72 weeks
|
72 weeks
|
Viral suppression (defined as plasma HIV-1 RNA levels <50 copies/mL) at and prior to week 24 after ART discontinuation
Time Frame: 24 weeks
|
24 weeks
|
Viral rebound defined as confirmed HIV-1 RNA>200 copies/mL by week 12 and through Step 2.
Time Frame: 72 weeks
|
72 weeks
|
Frequency of participants who maintain off ART and do not meet ART resumption criteria by study week.
Time Frame: 72 weeks
|
72 weeks
|
Frequency of participants who resume ART based virologic or immunologic criteria (i.e. viral load, CD4 cell, or development of severe acute retroviral syndrome).
Time Frame: 72 weeks
|
72 weeks
|
Concentration of 3BNC117-LS and 10-1074-LS at the time of viral rebound.
Time Frame: 72 weeks
|
72 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Katharine J Bar, M.D., University of Pennsylvania
- Study Chair: Marina Caskey, M.D., The Rockefeller University Non-Network CRS
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
Other Study ID Numbers
- A5364
- 37546 (Other Identifier: DAIDS-ES ID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
- With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
- For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
- By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on 3BNC117-LS
-
International AIDS Vaccine InitiativeBrigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller UniversityActive, not recruitingHIV-1-infectionUnited States, Uganda, Kenya, Rwanda, South Africa
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingHIV-1-infectionMalawi, South Africa, Botswana
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting
-
National Institute of Allergy and Infectious Diseases...Recruiting
-
Rockefeller UniversityCompleted
-
Imperial College LondonBill and Melinda Gates Foundation; University of Oxford; Rockefeller UniversityRecruitingHIV/AIDS and InfectionsDenmark, United Kingdom
-
Gilead SciencesCompleted
-
Rockefeller UniversityCompletedHuman Immunodeficiency VirusUnited States
-
Rockefeller UniversityNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsCompletedHuman Immunodeficiency VirusUnited States
-
National Institute of Allergy and Infectious Diseases...Gilead Sciences; University of OxfordRecruitingHIV-1-infectionUnited States, Brazil